◎ Sugi Atlas

Atlas / Drug / Pazopanib

Pazopanib

drug
On this page

Also known as GW-786034GW786034NSC-752782VotrientSID103905642SID124899319SID144206725SID170465625Pazopanib hydrochlorideÊPazopanib hydrochlorideÂ

Summary

Pazopanib (CHEMBL477772) is an approved small-molecule antineoplastic agent (ATC L01EX03) targeting PDGFRB, KIT, and CSF1R; indicated across 52 conditions including neoplasm and renal cell carcinoma.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EX03
  • Targets: 7 (PDGFRB, KIT, CSF1R…)
  • Indications: 52 conditions
  • Clinical trials: 201
  • Chemistry: 437.5 Da · C21H23N7O2S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL477772
NamePazopanib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID10113978
ChEBICHEBI:71219
ATCL01EX03
Molecular formulaC21H23N7O2S
Molecular weight437.5
InChIKeyCUIHSIWYWATEQL-UHFFFAOYSA-N

SMILES: CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N

IUPAC name: 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide

ChEBI definition: A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.

Pharmacological roles (ChEBI): antineoplastic agent, tyrosine kinase inhibitor, vascular endothelial growth factor receptor antagonist, angiogenesis modulating agent.

Also known as: GW-786034, GW786034, NSC-752782, Pazopanib, Votrient, pazopanib, SID103905642, SID124899319, SID144206725, SID170465625, PAZOPANIB, Pazopanib hydrochlorideÊ

Parent form; salt/anhydrous children: CHEMBL1201733

Patent coverage: 6,092 distinct patent families (15,540 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 15,403 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PDGFRBplatelet derived growth factor receptor betaInhibition7.082.3%P09619
KITKIT proto-oncogene, receptor tyrosine kinaseInhibition6.850.5%P10721
CSF1Rcolony stimulating factor 1 receptorInhibition6.840%P07333
FGFR1fibroblast growth factor receptor 1Inhibition7.1311.5%P11362
FLT1fms related receptor tyrosine kinase 1Inhibition80.1%P17948
KDRkinase insert domain receptorInhibition7.521.1%P35968
FLT4fms related receptor tyrosine kinase 4Inhibition7.330.2%P35916

Broader ChEMBL bioactivity targets: 120 (assay-derived). Sample: Serine/threonine-protein kinase TAO2, ATP-binding cassette sub-family C member 4, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Receptor-interacting serine/threonine-protein kinase 3, Tyrosine-protein kinase Fyn, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, RAF proto-oncogene serine/threonine-protein kinase, Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma.

Bioactivity

ChEMBL activities: 309 potent at pChembl ≥ 5 of 314 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
CA129.05Ki0.9nMCHEMBL_ACT_25998291
KIT8.74Kd1.8nMCHEMBL_ACT_7596447
PDGFRB8.7Kd2nMCHEMBL_ACT_2899080
PDGFRB8.7Kd2nMCHEMBL_ACT_7596533
KIT8.64Kd2.3nMCHEMBL_ACT_2897038
KIT8.64Kd2.3nMCHEMBL_ACT_7596448
KIT8.55Kd2.8nMCHEMBL_ACT_2895938
KIT8.55Kd2.8nMCHEMBL_ACT_6220451
KIT8.55Kd2.8nMCHEMBL_ACT_7596443
KDR8.5Ki3.16nMCHEMBL_ACT_9630097
PDGFRB8.4Ki3.98nMCHEMBL_ACT_9588166
PDGFRA8.31Kd4.9nMCHEMBL_ACT_2899042
PDGFRA8.31Kd4.9nMCHEMBL_ACT_7598232
KDR8.3IC505.01nMCHEMBL_ACT_13418835
KIT8.19Kd6.5nMCHEMBL_ACT_2896962
KIT8.19Kd6.5nMCHEMBL_ACT_7596449
KDR8.1IC508nMCHEMBL_ACT_2561556
CSF1R8.1Kd7.9nMCHEMBL_ACT_2902387
CSF1R8.1Kd7.9nMCHEMBL_ACT_7598193
CA98.04Ki9.1nMCHEMBL_ACT_23184223
CA98.04Ki9.1nMCHEMBL_ACT_25998267
FLT18IC5010nMCHEMBL_ACT_18854172
FLT18IC5010nMCHEMBL_ACT_23289736
FLT18IC5010nMCHEMBL_ACT_2561549
CA17.92Ki12.1nMCHEMBL_ACT_25998223
KDR7.85Kd14nMCHEMBL_ACT_2891412
FLT17.85Kd14nMCHEMBL_ACT_2907356
FLT17.85Kd14nMCHEMBL_ACT_7596511
KDR7.85Kd14nMCHEMBL_ACT_7596518
FLT17.8Ki15.85nMCHEMBL_ACT_9661388

Target pathways

Aggregated over 7 target gene(s): PDGFRB, KIT, CSF1R, FGFR1, FLT1, KDR, FLT4.

Top Reactome pathways

70 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling3FGFR1, KIT, PDGFRB
VEGF binds to VEGFR leading to receptor dimerization3FLT1, FLT4, KDR
Constitutive Signaling by Aberrant PI3K in Cancer3FGFR1, KIT, PDGFRB
RAF/MAP kinase cascade3FGFR1, KIT, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling3FGFR1, KIT, PDGFRB
Neuropilin interactions with VEGF and VEGFR2FLT1, KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells2FLT4, KDR
PI3K Cascade1FGFR1
Developmental Biology1KIT
Signaling by SCF-KIT1KIT
Regulation of KIT signaling1KIT
Signal Transduction1KIT
Disease1KIT
Signaling by FGFR1 amplification mutants1FGFR1
Signaling by activated point mutants of FGFR11FGFR1
Downstream signal transduction1PDGFRB
Signaling by PDGF1PDGFRB
FGFR1b ligand binding and activation1FGFR1
FGFR1c ligand binding and activation1FGFR1
FGFR1c and Klotho ligand binding and activation1FGFR1
Negative regulation of the PI3K/AKT network1KIT
Generic Transcription Pathway1KIT
Integrin cell surface interactions1KDR
PI3K/AKT Signaling in Cancer1KIT
NCAM signaling for neurite out-growth1FGFR1
VEGFA-VEGFR2 Pathway1KDR
Signal transduction by L11FGFR1
Other interleukin signaling1CSF1R
VEGFR2 mediated cell proliferation1KDR
Phospholipase C-mediated cascade: FGFR11FGFR1

Dominant GO biological processes

GO termTargets
positive regulation of cell population proliferation7
protein autophosphorylation7
protein phosphorylation7
cell migration7
cell surface receptor protein tyrosine kinase signaling pathway6
peptidyl-tyrosine phosphorylation6
positive regulation of cell migration6
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction6
angiogenesis5
positive regulation of MAPK cascade5
positive regulation of ERK1 and ERK2 cascade4
signal transduction3
positive regulation of MAP kinase activity3
chemotaxis3
regulation of cell shape3

Indications & clinical

Indications

52 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm3MONDO:0005070EFO:0000616
renal cell carcinoma3MONDO:0005086EFO:0000681
sarcoma3MONDO:0005089EFO:0000691
ovarian neoplasm3MONDO:0021068EFO:0003893
clear cell renal carcinoma3MONDO:0005005EFO:0000349
soft tissue sarcoma3MONDO:0018078EFO:1001968
ovarian cancer3MONDO:0008170MONDO:0008170
leiomyosarcoma2MONDO:0005058EFO:0000564
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
liposarcoma2MONDO:0005060EFO:0000569
prostate adenocarcinoma2MONDO:0005082EFO:0000673
osteosarcoma2MONDO:0009807EFO:0000637
small cell lung carcinoma2MONDO:0008433EFO:0000702
germ cell tumor2MONDO:0005040EFO:0000514
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
chondrosarcoma2MONDO:0008977EFO:0000333
breast neoplasm2MONDO:0021100EFO:0003869
thyroid gland carcinoma2MONDO:0015075EFO:0002892
acute myeloid leukemia2MONDO:0018874EFO:0000222
melanoma2MONDO:0005105EFO:0000756
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
angiosarcoma2MONDO:0016982EFO:0003968
alveolar soft part sarcoma2MONDO:0011655EFO:0007143
gliosarcoma2MONDO:0016681EFO:1001465
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
macular degeneration2MONDO:0003004EFO:0009606
salivary gland cancer2MONDO:0004669MONDO:0000521
gastric neoplasm2MONDO:0021085MONDO:0001056
peritoneal neoplasm2MONDO:0006901MONDO:0002087
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
kidney cancer2MONDO:0002367MONDO:0002367
lung neoplasm2MONDO:0021117MONDO:0008903
solitary fibrous tumor2MONDO:0016238MONDO:0016238
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
dermatofibrosarcoma protuberans2MONDO:0011934MONDO:0011934
hereditary hemorrhagic telangiectasia2MONDO:0019180MONDO:0019180
lymphedema2MONDO:0019297MONDO:0019297
kidney neoplasm2MONDO:0021163EFO:0003865
central nervous system neoplasm2MONDO:0006130EFO:1000158
paraganglioma2MONDO:0000448EFO:1000453
colorectal adenocarcinoma1MONDO:0005008EFO:0000365
glioblastoma1MONDO:0018177EFO:0000519
hepatocellular carcinoma1MONDO:0007256EFO:0000182
corneal neovascularization1MONDO:0006713EFO:1000880
lymphoma1MONDO:0005062EFO:0000574
psoriasis1MONDO:0005083EFO:0000676

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 201.

Phase distribution

PhaseTrials
PHASE298
PHASE153
PHASE1/PHASE216
PHASE313
Not specified11
PHASE44
PHASE2/PHASE34
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01205230PHASE4COMPLETEDVEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
NCT01521715PHASE4COMPLETEDFirst Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
NCT02555748PHASE4COMPLETEDTherapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
NCT05949424PHASE4UNKNOWNOPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT02180867PHASE2/PHASE3ACTIVE_NOT_RECRUITINGRadiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT03592472PHASE3RECRUITINGA Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
NCT03850964PHASE2/PHASE3ACTIVE_NOT_RECRUITINGEffects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
NCT05432791PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
NCT06263231PHASE3ACTIVE_NOT_RECRUITINGA Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
NCT06726421PHASE3RECRUITINGSystemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT00334282PHASE3COMPLETEDSafety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
NCT00387764PHASE3COMPLETEDExtension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
NCT00720941PHASE3COMPLETEDPazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT00753688PHASE3COMPLETEDPazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
NCT00775307PHASE2/PHASE3COMPLETEDAdjuvant Pazopanib in Stage I NSCLC
NCT00866697PHASE3COMPLETEDEfficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01064310PHASE3COMPLETEDPatient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
NCT01235962PHASE3COMPLETEDA Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
NCT01613846PHASE3COMPLETEDPhase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
NCT02979899PHASE3COMPLETEDTrial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
NCT03260894PHASE3COMPLETEDPembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT01217931PHASE2ACTIVE_NOT_RECRUITINGSequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
NCT02203760PHASE2ACTIVE_NOT_RECRUITINGPazopanib Vs. Pazopanib Plus Gemcitabine
NCT02331498PHASE1/PHASE2ACTIVE_NOT_RECRUITINGPhase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
NCT05180695PHASE1/PHASE2ACTIVE_NOT_RECRUITINGHDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
NCT05679921PHASE2RECRUITINGPazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
NCT06239272PHASE1/PHASE2RECRUITINGNRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06739395PHASE2RECRUITINGPrecision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
NCT06816771PHASE2RECRUITINGEvaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
NCT06895733PHASE1/PHASE2RECRUITINGStudy of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
NCT07087158PHASE2NOT_YET_RECRUITINGA Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
NCT00244764PHASE2COMPLETEDGW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
NCT00256880PHASE2COMPLETEDPazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
NCT00281632PHASE2COMPLETEDA Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
NCT00297258PHASE2COMPLETEDPazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
NCT00347919PHASE2COMPLETEDPazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
NCT00350727PHASE2COMPLETEDPazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
NCT00367679PHASE2COMPLETEDPazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
NCT00430781PHASE2COMPLETEDPazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
NCT00549328PHASE2TERMINATEDMonotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

235 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CrizotinibChEMBL + PubChemPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
REGORAFENIBChEMBL + PubChemPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
AXITINIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
FEDRATINIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
MIDOSTAURINChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
NINTEDANIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
SORAFENIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
SUNITINIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
VANDETANIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
BRIVANIBChEMBLPhase 3CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
CEDIRANIBChEMBLPhase 3CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
DOVITINIBChEMBLPhase 3CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
LESTAURTINIBChEMBLPhase 3CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
LINIFANIBChEMBLPhase 3CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
MOTESANIBChEMBLPhase 3CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
SEMAXANIBChEMBLPhase 3CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
CENISERTIBChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
DORAMAPIMODChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
FORETINIBChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
ILORASERTIBChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
R-406ChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
RAF-265ChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
SU-014813ChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
TANDUTINIBChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
TOZASERTIBChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
AfatinibPubChemApprovedCSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
SelumetinibPubChemApprovedCSF1R, FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
GEFITINIBChEMBL + PubChemPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT
DASATINIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, KDR, KIT, PDGFRB
ENTRECTINIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, FLT4, KDR, KIT
LENVATINIBChEMBLPhase 4 (approved)FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
PONATINIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT1, KDR, KIT, PDGFRB
QUIZARTINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT4, KDR, KIT, PDGFRB
TIVOZANIBChEMBLPhase 4 (approved)FGFR1, FLT1, FLT4, KDR, KIT, PDGFRB
VATALANIBChEMBLPhase 3CSF1R, FLT1, FLT4, KDR, KIT, PDGFRB
DEFOSBARASERTIBChEMBLPhase 2CSF1R, FLT1, FLT4, KDR, KIT, PDGFRB
REBASTINIBChEMBLPhase 2CSF1R, FGFR1, FLT1, FLT4, KDR, KIT
IdelalisibPubChemApprovedCSF1R, FGFR1, FLT1, FLT4, KIT, PDGFRB
BRIGATINIBChEMBLPhase 4 (approved)CSF1R, FGFR1, FLT4, KDR, KIT
CABOZANTINIBChEMBLPhase 4 (approved)FGFR1, FLT1, FLT4, KDR, KIT
ERLOTINIBChEMBLPhase 4 (approved)FLT1, FLT4, KDR, KIT, PDGFRB
INFIGRATINIBChEMBLPhase 4 (approved)FGFR1, FLT1, FLT4, KDR, KIT
NINTEDANIB ESYLATEChEMBLPhase 4 (approved)FGFR1, FLT1, FLT4, KDR, PDGFRB
PEXIDARTINIBChEMBLPhase 4 (approved)CSF1R, FLT1, KDR, KIT, PDGFRB
BFH-772ChEMBLPhase 2FLT1, FLT4, KDR, KIT, PDGFRB
CEP-32496ChEMBLPhase 2CSF1R, FLT1, KDR, KIT, PDGFRB
LUCITANIBChEMBLPhase 2FGFR1, FLT1, FLT4, KDR, PDGFRB
MK-2461ChEMBLPhase 2FGFR1, FLT1, FLT4, KDR, PDGFRB
OSI-632ChEMBLPhase 2FGFR1, FLT1, FLT4, KDR, PDGFRB
IMATINIBChEMBL + PubChemPhase 4 (approved)CSF1R, KDR, KIT, PDGFRB
CANERTINIBChEMBLPhase 3FLT1, KDR, KIT, PDGFRB
ENZASTAURINChEMBLPhase 3FGFR1, FLT4, KIT, PDGFRB
ORANTINIBChEMBLPhase 3FGFR1, FLT1, KDR, PDGFRB
SURUFATINIBChEMBLPhase 3FGFR1, FLT1, FLT4, KDR
AT-9283ChEMBLPhase 2FGFR1, FLT1, FLT4, KDR
CEP-11981ChEMBLPhase 2CSF1R, FGFR1, FLT1, KDR
DANUSERTIBChEMBLPhase 2FGFR1, FLT4, KDR, KIT
ENMD-2076ChEMBLPhase 2CSF1R, FGFR1, KDR, KIT
MILCICLIBChEMBLPhase 2FGFR1, FLT4, KIT, PDGFRB
TELATINIBChEMBLPhase 2FLT4, KDR, KIT, PDGFRB

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot